OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Rheumatology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	1752
Research in Brief	1466
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	571
Can contextual factors improve clarity of the results from clinical trials of low back pain?	365
A disseminated gonococcal infection with spinal locations	262
Biological disease-modification in axial spondyloarthritis: insights from MRI	229
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	112
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	111
Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial	104
Reigniting the burnt-out health-care workforce	103
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	99
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	98
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	90
Patient involvement in digital rheumatology: lessons from practice	82
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	82
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	81
Women in rheumatology in Africa	75
Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance	72
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	70
Research in Brief	67
Assessing glucocorticoid toxicity: are the measures sensitive enough?	66
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	66
Correction to Lancet Rheumatol 2026; 8: e5–6	64
Biosimilars and the era of interchangeability	59
Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE	54

Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	53
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	52
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	52
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	49
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	48
Beyond MRI positivity in axial spondyloarthritis: the ubiquity of bone marrow oedema and risk of overinterpretation	48
Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology–European League A	47
Addition of aerobic physical activity to resistance exercise for hip osteoarthritis (PHOENIX): a randomised comparative effectiveness trial	47
Pain in clinical trials for knee osteoarthritis: estimation of regression to the mean	46
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	45
Baricitinib and ruxolitinib use through the UK HLH Network	44
When and how chronicity develops in rheumatoid arthritis: towards a temporal and tissue-integrated perspective	43
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	43
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	42
Additional SARS-CoV-2 vaccine doses: a little is better than none	41
Clinical trial design: time to accelerate the pace of change?	41
Urgent reform needed for homecare medicines services	41
Let's talk about sex in interstitial lung disease	39
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome	38
Tackling heterogeneity in Sjögren's disease	38
Research in Brief	38
Kanon Jatuworapruk: bringing out the enjoyment in life	38
Optimal non-opioid analgesic combinations after total hip arthroplasty – Authors' reply	37
Constitutional symptoms of severe childhood-onset polyarteritis nodosa	35
Correction to Lancet Rheumatol 2025; 7: e851–63	35
Clinical hypnosis and pain management in sharp debridement of skin ulcers in immune-mediated inflammatory diseases	34
10 years of SAGER sees progress, but not parity	34
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study	34
Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial	34
Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study	33
Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study	33
Fetal and maternal outcome in the pregnancies of patients with systemic sclerosis and very early diagnosis of systemic sclerosis in France: a prospective study	33
The 2024 US election—voting for equitable health care	33
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases	32
Advancing research and equity through collaboration	32
Explanation for substandard of care comparators in rheumatology randomised trial protocols	32
Are we ready for home spirometry for systemic sclerosis-associated ILD?	32
Enabling and supporting public and patient involvement in arthritis research	31
Suspending methotrexate for 2 weeks after COVID-19 vaccination	31
Digital self-management for back pain in the UK	31
Correction to Lancet Rheumatol 2025; published online Feb 27. https://doi.org/10.1016/S2665-9913(24)00348-5	31
Sex differences of brain oscillatory activity and quantitative sensory testing in people with chronic osteoarthritis pain: a cross-sectional study	31
Better diagnostic tools needed for biopsy-negative giant cell arteritis	31
Research in Brief	31
Challenges in the therapeutic management of psoriatic arthritis	30
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level	30
JIA care under the microscope	30
Can we prevent the onset of rheumatoid arthritis in patients with high-risk features?	30
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national co	30
Correction to Lancet Rheumatol 2026; 8: e265–73	29

Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials	29
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort	28
Cranial involvement in giant cell arteritis	28
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study	28
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis – Authors' reply	27
For SLE activity and glucocorticoids: aim low	27
Beneficial side-effects of colchicine for patients with gout	27
Top priorities for prehabilitation in orthopaedics	26
Penélope Palominos: rheumatology by sight and touch	26
Reconciling immunotherapy and autoimmunity: not for the faint of heart	26
Coronary polyarteritis nodosa	26
Gout in central Asia: a few things make a big difference	26
Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sjögren's disease activity: a multicentre, retrospective, observational study	26
Sex-related differences in health-care use in adult patients with inflammatory arthritis in Ontario, Canada: a population-based cohort study	26
Polychondritis in a child	26
Jean Liew: from Bronte scholar to social media influencer	25
COP27 Climate Change Conference: urgent action needed for Africa and the world	25
Sex and gender impact on achievement of remission in people with rheumatoid arthritis in Switzerland: a cohort study	24
Systemic sclerosis and pregnancy: advancing prospective evidence for risk stratification and postpartum care	24
The impact of COVID-19 on care of early inflammatory arthritis in the UK	24
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study	24
Pain and wellbeing in young people with arthritis	24
Vascular Ehlers-Danlos syndrome: a heritable condition with potentially fatal consequences	24
Digital remote monitoring in rheumatology: using health economics to support wider adoption	23
Microscopic polyangiitis presenting with retinal frosted branch angiitis	23
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial	23
Advancing predictive accuracy for shoulder replacement surgery	23
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study	23
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality among patients who are immunocompromised with COVID-19 in Hong Kong: a retrospective cohort study	23
Coronary polyarteritis nodosa in a young adult	23
Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case–control study	23
Correction to Lancet Rheumatol 2023; 5: e461–73	22
Time to revisit the therapeutic benefits of exercise for osteoarthritis?	22
Role of plasma exchange in ANCA-associated vasculitis – Authors' reply	21
Ustekinumab with or without methotrexate for psoriatic arthritis?	21
Rheumatology congresses post COVID-19: we cannot regress	21
Prize trends in rheumatology: the Gender Award Gap	21
Effectiveness of a fourth mRNA dose among individuals with systemic autoimmune rheumatic diseases during the Omicron era	20
Pregnant pause in women with rheumatoid arthritis	20
DAVIX: a vascular outcome measure in systemic sclerosis	20
Research in Brief	20
Vasculitis management remains a challenge during pregnancy	19
Cognitive impairment in individuals with rheumatic diseases: the role of systemic inflammation, immunomodulatory medications, and comorbidities	19
Impact of the COVID-19 pandemic on autoimmune rheumatic disease diagnoses	19
Prevention of psoriatic arthritis: the next frontier	19
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study	19
Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial	18
Global, regional, and national burden of other musculoskeletal disorders, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	18
Silent patients, silent disease: misalignment in patient-initiated follow-up	18
Susac syndrome: challenges of interpreting treatment data in a rare disease	18
Substantiation of trophoblast transport of maternal anti-SSA/Ro autoantibodies in fetuses with rapidly progressive cardiac injury: implications for neonatal Fc receptor blockade	18
Palliative care in patients with rheumatic diseases	18
Correction to Lancet Rheumatol 2022; 4: e853–63	17
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	17
Psoriatic arthritis: strategy shaping treatment	17
Correction to Lancet Rheumatol 2022; 4: e177–87	17
Research in Brief	16
Vasculitis: the promising road ahead	16
Research in Brief	16
Cardiovascular risk in gout: time for action	16
Herpes zoster vaccination and flares in rheumatic diseases	16
Research in Brief	16
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	16
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	15
Rheumatic cognitive impairment: a new clinical entity?	15
Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial	15
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-	15
The influence of safety warnings on the prescribing of JAK inhibitors	15
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	15
Forging ahead on fibromyalgia	15
The same genotype gives rise to a spectrum of disorders	15
Calcium pyrophosphate deposition disease	14
Predictors of pregnancy outcomes in SLE	14
Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study	14
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	14
Progressive bone destruction of the hand in Gorham–Stout disease	14
Debate over interventional procedures for chronic spine pain	14
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	14
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	14
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	13

Michael Barrett: navigating hostile terrain	13
Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study	13
Promise and challenges of mesenchymal stromal cell therapy in severe SLE	13
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	13
Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial	13
Narendra Kumar Bagri: taking paediatric rheumatology in India to new heights	13
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	13
An imaging crisis in axial spondyloarthritis	13
Getting better at quantifying the toxicity of glucocorticoids	13
Aspirin desensitisation in pregnant individuals with autoimmune disease	13
Predictors of pregnancy outcomes in SLE	13
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	13
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	12
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	12
Contesting the BACPAP consortium's consensus – Authors' reply	12
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	12
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	12
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	12
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply	12
Research in Brief	12
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease	12
Preclinical or subclinical rheumatoid arthritis-associated interstitial lung disease: misleading terms with potentially deleterious consequences	12
Inclusion of pregnant populations in clinical trials in China: the ethical considerations	12
Modelling allopurinol-induced severe adverse cutaneous reactions	12
Kimberly Templeton: creative change maker	11
Debashish Danda	11
Dual JAK and ROCK inhibition and comorbidities in rheumatoid arthritis	11
Coronary polyarteritis nodosa in a young adult – Authors' reply	11
Long COVID in inflammatory rheumatic diseases—what's in a name?	11
Research in Brief	11
The stark reality of living with arthritis in the UK	11
Including refractory systemic sclerosis-associated GAVE in research agendas	11
Research in Brief	11
Early screening for rheumatoid arthritis-associated interstitial lung disease: statistical nuances challenge the role of disease activity – Authors' reply	11
Risk-based stratified primary care for common musculoskeletal pain presentations (STarT MSK): a cluster-randomised, controlled trial	10
The Gout by Dorian Haskard	10
Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial	9
Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study	9
Irish experiences of parenting with early inflammatory arthritis: a qualitative study	9
Barriers to CAR T-cell therapy in rheumatology	9
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial	9
When the game changes: efficacy of rituximab in systemic sclerosis	9
Colchicum and gout: two millennia of therapeutic continuity	9
Synovial tissue for personalised medicine in rheumatoid arthritis: hype or hope?	9
Precision medicine in rheumatoid arthritis: unravelling sex-driven differences in response to treatment	9